SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001558370-24-008133
Filing Date
2024-05-14
Accepted
2024-05-14 16:06:15
Documents
14
Period of Report
2024-05-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kala-20240514x8k.htm   iXBRL 8-K 32737
2 EX-99.1 kala-20240514xex99d1.htm EX-99.1 83078
  Complete submission text file 0001558370-24-008133.txt   242749

Data Files

Seq Description Document Type Size
3 EX-101.SCH kala-20240514.xsd EX-101.SCH 3126
4 EX-101.LAB kala-20240514_lab.xml EX-101.LAB 15266
5 EX-101.PRE kala-20240514_pre.xml EX-101.PRE 9658
18 EXTRACTED XBRL INSTANCE DOCUMENT kala-20240514x8k_htm.xml XML 4676
Mailing Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476
Business Address 1167 MASSACHUSETTS AVENUE ARLINGTON MA 02476 781-996-5252
KALA BIO, Inc. (Filer) CIK: 0001479419 (see all company filings)

IRS No.: 270604595 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38150 | Film No.: 24944263
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)